Metagenomi Therapeutics Statistics
Total Valuation
MGX has a market cap or net worth of $39.29 million. The enterprise value is -$43.66 million.
| Market Cap | 39.29M |
| Enterprise Value | -43.66M |
Important Dates
The next estimated earnings date is Tuesday, November 10, 2026, after market close.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MGX has 37.78 million shares outstanding. The number of shares has increased by 1.07% in one year.
| Current Share Class | 37.78M |
| Shares Outstanding | 37.78M |
| Shares Change (YoY) | +1.07% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 10.57% |
| Owned by Institutions (%) | 17.40% |
| Float | 25.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.91 |
| Forward PS | 4.67 |
| PB Ratio | 0.35 |
| P/TBV Ratio | 0.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.50, with a Debt / Equity ratio of 0.34.
| Current Ratio | 4.50 |
| Quick Ratio | 4.40 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -60.61% and return on invested capital (ROIC) is -32.31%.
| Return on Equity (ROE) | -60.61% |
| Return on Assets (ROA) | -28.19% |
| Return on Invested Capital (ROIC) | -32.31% |
| Return on Capital Employed (ROCE) | -68.85% |
| Weighted Average Cost of Capital (WACC) | 4.15% |
| Revenue Per Employee | $120,009 |
| Profits Per Employee | -$827,097 |
| Employee Count | 113 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -190,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.57% in the last 52 weeks. The beta is 0.70, so MGX's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -60.57% |
| 50-Day Moving Average | 1.18 |
| 200-Day Moving Average | 1.37 |
| Relative Strength Index (RSI) | 35.23 |
| Average Volume (20 Days) | 151,075 |
Short Selling Information
The latest short interest is 1.43 million, so 3.79% of the outstanding shares have been sold short.
| Short Interest | 1.43M |
| Short Previous Month | 1.44M |
| Short % of Shares Out | 3.79% |
| Short % of Float | 5.60% |
| Short Ratio (days to cover) | 8.68 |
Income Statement
In the last 12 months, MGX had revenue of $13.56 million and -$93.46 million in losses. Loss per share was -$2.49.
| Revenue | 13.56M |
| Gross Profit | -75.04M |
| Operating Income | -100.57M |
| Pretax Income | -93.65M |
| Net Income | -93.46M |
| EBITDA | -95.40M |
| EBIT | -100.57M |
| Loss Per Share | -$2.49 |
Balance Sheet
The company has $120.66 million in cash and $37.72 million in debt, with a net cash position of $82.94 million or $2.20 per share.
| Cash & Cash Equivalents | 120.66M |
| Total Debt | 37.72M |
| Net Cash | 82.94M |
| Net Cash Per Share | $2.20 |
| Equity (Book Value) | 112.57M |
| Book Value Per Share | 2.98 |
| Working Capital | 96.84M |
Cash Flow
In the last 12 months, operating cash flow was -$85.49 million and capital expenditures -$309,000, giving a free cash flow of -$85.80 million.
| Operating Cash Flow | -85.49M |
| Capital Expenditures | -309,000 |
| Depreciation & Amortization | 5.16M |
| Net Borrowing | n/a |
| Free Cash Flow | -85.80M |
| FCF Per Share | -$2.27 |
Margins
| Gross Margin | n/a |
| Operating Margin | -741.58% |
| Pretax Margin | -690.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MGX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.07% |
| Shareholder Yield | -1.07% |
| Earnings Yield | -236.75% |
| FCF Yield | -217.33% |
Analyst Forecast
The average price target for MGX is $7.00, which is 573.08% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.00 |
| Price Target Difference | 573.08% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -43.85% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MGX has an Altman Z-Score of -3.42 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.42 |
| Piotroski F-Score | 1 |